国新健康(000503) - 2021 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2021 reached ¥49,160,202.57, an increase of 70.35% compared to the same period last year[5] - Net profit attributable to shareholders was -¥31,767,200.47, a decrease of 25.09% year-on-year[5] - The net profit for the quarter was a loss of ¥127,465,744.41, an improvement from a loss of ¥163,022,523.14 in the same period last year[42] - The company reported a net loss attributable to shareholders of the parent company of ¥127,324,268.01, compared to a loss of ¥162,047,679.19 in the previous year[42] - The total comprehensive income attributable to the parent company was -129,962,216.67 CNY, a decrease from -177,187,414.71 CNY in the previous period, reflecting a significant decline[45] - Basic and diluted earnings per share were both -0.1417 CNY, compared to -0.1803 CNY in the previous period, indicating a slight improvement[45] Cash Flow and Financial Activities - The company reported a net cash flow from operating activities of -¥148,080,273.01, a decline of 12.25% compared to the same period last year[5] - Cash inflows from operating activities totaled 118,889,034.79 CNY, up from 86,289,492.37 CNY in the previous period, showing a growth of approximately 37.6%[49] - Cash outflows from operating activities amounted to 266,969,307.80 CNY, compared to 218,207,079.28 CNY in the previous period, representing an increase of about 22.3%[49] - The net cash flow from operating activities was -148,080,273.01 CNY, worsening from -131,917,586.91 CNY in the previous period[49] - The net cash flow from investing activities was 9,780,628.46 CNY, a recovery from -7,744,086.85 CNY in the previous period[49] - The net cash flow from financing activities was 32,436,493.08 CNY, slightly down from 34,903,454.17 CNY in the previous period[49] - The company received 20,000,000.00 CNY in borrowings during the financing activities, a decrease from 35,000,000.00 CNY in the previous period[49] - The impact of exchange rate changes on cash and cash equivalents was -2,917,255.38 CNY, an improvement from -9,037,651.96 CNY in the previous period[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,181,350,672.75, down 8.90% from the end of the previous year[5] - The company’s equity attributable to shareholders decreased to ¥830,896,196.55, a decline of 13.55% compared to the previous year[5] - The total liabilities and equity amounted to ¥1,181,350,672.75, down from ¥1,296,817,917.19[38] - The total current liabilities increased to ¥347,525,975.92 from ¥332,600,788.33, marking an increase of approximately 4%[38] - Current liabilities totaled 332,600,788.33, showing a decrease of 5,222,284.78 compared to the previous period[59] - Total liabilities increased to 332,600,788.33, with a rise of 14,734,556.72 from the last reporting period[59] Research and Development - R&D investment increased to ¥20,863,756.28, representing a growth of 71.32% year-on-year, reflecting the company's focus on new product and technology development[11] - Research and development expenses rose to ¥12,621,987.78, compared to ¥5,595,884.74 in the prior year, reflecting a growth of approximately 126%[39] Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,918[12] - The largest shareholder, China Oceanwide Holdings, holds 25.98% of shares, totaling 235,702,593 shares[12] Strategic Investments and Acquisitions - The company has completed the acquisition of a 5.05% stake in Yiyong Technology for RMB 24.6 million and plans to increase its stake to 10.02% with an additional investment of RMB 57.4 million[17] - The company will invest RMB 12 million to increase its stake in China Medical and Pharmaceutical Emergency Guarantee Platform to 8%[20] - A strategic cooperation framework agreement was signed with Miaojian Health to leverage both companies' strengths in healthcare services[21] - The company provided a guarantee of up to RMB 10 million for its wholly-owned subsidiary, Beijing Haixie Zhikang Technology Development Co., Ltd.[22] - The company has increased its wholly-owned subsidiary, Beijing Yihong Medical Technology Service Co., Ltd., with an investment of USD 35 million[23] Incentive Plans and Future Targets - The company has established a long-term incentive plan to attract and retain talent, with performance indicators including a compound annual growth rate of revenue not less than 45%, 41.3%, and 37.8% compared to 2019[24] - The company aims for revenue targets of RMB 396.06 million, RMB 517.87 million, and RMB 645.50 million for the years 2022 to 2024, reflecting high growth potential[24] Other Financial Metrics - The company recorded a significant increase in other income, totaling ¥114,727.56, up 40.05% year-on-year[11] - The company’s financial expenses rose to ¥18,835.52, a significant increase due to reduced interest income from bank deposits[11] - The company’s retained earnings decreased to ¥51,535,196.77 from ¥179,148,203.74, indicating a decline of about 71%[38] - Other comprehensive income after tax showed a loss of ¥2,637,948.66, compared to a loss of ¥15,139,735.52 in the prior year[42] - The company has completed the first grant of its restricted stock incentive plan, increasing total shares from 898,822,204 to 907,215,204[27] - The company attempted to sell a 45% stake in Guangdong Haihong for a minimum price of RMB 137.73 million, but the project has been withdrawn due to lack of qualified buyers[28] - The company received approval for its stock incentive plan from the State-owned Assets Supervision and Administration Commission in April 2021[26]